Septal reduction therapy using nonalcohol agent in hypertrophic obstructive cardiomyopathy: Single center experience

Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions
Serkan AsilKudret Aytemir

Abstract

Percutaneous septal reduction therapy by either alcohol or nonalcohol agents is an alternative approach to surgery in drug-refractory symptomatic patients with hypertrophic obstructive cardiomyopathy (HOCM). Nonalcohol agents have some advantages and disadvantages over alcohol during the procedure. Nowadays, a novel non-alcohol agent, named as Ethylene-vinyl alcohol (EVOH) copolymer (Onyx® and Squid® ), is used during septal ablation. Thus, in this study, we aimed to evaluate both acute and long-term efficacy and safety profile of EVOH during septal ablation in HOCM. A total of 25 patients (52% female; mean age: 55.8 ± 17.1 years) with symptomatic HOCM were enrolled in the study. All subjects underwent clinical and laboratory assessment before and after the procedure. Peak left ventricular outflow tract (LVOT) gradient was significantly reduced just after the procedure (68 vs. 20 mmHg; P < 0.001). Peak serum creatine kinase-myocardial band and troponin I levels were 112 (35-282) ng/ml and 11 (4-93) ng/ml. EVOH embolization to diagonal artery was observed in 1 patient (4%) and the complete atrioventricular block was noted in 2 (8%) patients. During the 12-month follow-up, there was no mortality. There was a significant improveme...Continue Reading

References

Sep 15, 2000·Journal of the American College of Cardiology·Nasser M LakkisW H Spencer
Sep 3, 2004·European Journal of Echocardiography : the Journal of the Working Group on Echocardiography of the European Society of Cardiology·Lothar FaberDieter Horstkotte
Dec 24, 2004·Journal of Endovascular Therapy : an Official Journal of the International Society of Endovascular Specialists·C Michael GrossRainer Dietz
Oct 11, 2005·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·David R HolmesRick A Nishimura
Feb 7, 2006·European Journal of Echocardiography : the Journal of the Working Group on Echocardiography of the European Society of Cardiology·Roberto M LangEuropean Association of Echocardiography, European Society of Cardiology
Aug 3, 2006·Journal of Interventional Cardiology·Mahboob AlamNasser M Lakkis
Feb 7, 2007·Expert Review of Medical Devices·Michael AyadRobert A Mericle
May 26, 2007·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Ali OtoAli Deniz
Dec 12, 2007·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Horst KuhnChristoph Stellbrink
Dec 25, 2007·The Annals of Thoracic Surgery·Nicholas G SmediraEugene H Blackstone
Jul 2, 2008·Circulation·Paul SorajjaDavid R Holmes
Oct 1, 2008·Neurosurgery·Pankaj GoreFelipe C Albuquerque
Feb 24, 2009·European Heart Journal·Mahboob AlamNasser M Lakkis
Oct 27, 2010·Journal of Interventional Cardiology·Ali OtoGiray Kabakci
Oct 12, 2013·Polish journal of radiology·Maciej SzajnerMałgorzata Szczerbo-Trojanowska
Nov 29, 2013·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Josef VeselkaHorst Kuhn
Mar 25, 2016·JRSM Cardiovascular Disease·Sercan OkutucuAli Oto

Related Concepts

Onyx 18
Pilot Project Data
Idiopathic Hypertrophic Subaortic Stenosis
Drug Combinations
Embolization, Therapeutic
Polyvinyls
Tantalum
2D Doppler Echocardiography
Nested Case-Control Studies
Left Ventricular Function

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.